Document Detail


bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells.
MedLine Citation:
PMID:  8628007     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Parental and multidrug resistant HL60 leukemia cell lines were used to study coupling of expression of apoptotic/cytostatic (bcl-2, bax, bclxL, p21/Waf1, and c-myc) genes during differentiation. The multidrug resistant HL60 cell line, HL60/ADR, was less sensitive than parental cells to cytostatic activity of low (0.4-2 ng/ml) doses of PMA. However, during treatment with standard differentiating doses of PMA (10 ng/ml), no difference between the two cell lines in cytostasis and differentiation was found. Downregulation of c-myc and upregulation of p21/Waf1 proteins showed the same time-course in both cell lines. The bcl-2 mRNA was rapidly downregulated while bax and bclxL gene expression was not altered in both differentiating HL60 and HL60/ADR cells. Significant downregulation of bcl-2 protein occurred only in parental HL60 cells. In HL60/ADR, despite rapid cessation of bcl-2 protein synthesis, almost no change in steady-state bcl-2 protein level was found. The lack of bcl-2 protein downregulation was a result of the prolonged half-life of this protein in HL60/ADR cells. Thus, although downregulation of bcl-2 mRNA is coupled to differentiation, actual loss of bcl-2 protein is not required for accomplishment of the differentiation program.
Authors:
M V Blagosklonny; M Alvarez; A Fojo; L M Neckers
Related Documents :
7608287 - Reduction of extracellular matrix protein expression in human amnion epithelial cells b...
19399397 - Destruction of gastric cancer cells to mesothelial cells by apoptosis in the early peri...
22618587 - Intrastriatal b-cell administration limits infarct size after stroke in b-cell deficien...
18979497 - Pax9 mediated cell survival in oral squamous carcinoma cell enhanced by c-myb.
8748697 - Kinetics of nitric oxide synthase induction by propionibacterium avidum and lipopolysac...
21388137 - Epigallocatechin-3 gallate inhibits invasion, epithelial-mesenchymal transition, and tu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Leukemia research     Volume:  20     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-06-21     Completed Date:  1996-06-21     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  101-7     Citation Subset:  IM    
Affiliation:
Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blotting, Western
Cell Differentiation / drug effects
Down-Regulation*
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Genes, myc
HL-60 Cells / drug effects,  pathology*
Half-Life
Humans
Leukemia, Promyelocytic, Acute / genetics,  pathology
Oncogene Protein p21(ras) / genetics
Polymerase Chain Reaction
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-myc / genetics
Tetradecanoylphorbol Acetate / pharmacology
bcl-2-Associated X Protein
Chemical
Reg. No./Substance:
0/BAX protein, human; 0/Proto-Oncogene Proteins; 0/Proto-Oncogene Proteins c-bcl-2; 0/Proto-Oncogene Proteins c-myc; 0/bcl-2-Associated X Protein; 16561-29-8/Tetradecanoylphorbol Acetate; EC 3.6.5.2/Oncogene Protein p21(ras)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rapid resolution of necrolytic migratory erythema after glucagonoma resection.
Next Document:  Infrequent microsatellite instability during the evolution of myelodysplastic syndrome to acute myel...